To evaluate different doses of ivermectin in adult patients with mild COVID-19 and to evaluate the effect of ivermectin on mortality and clinical consequences.

Authors: Ahorsu DK, Adjaottor ES, Lam BY PMID: 34202739 PMCID: PMC8301762 DOI: 10.3390/brainsci11070840 Abstract This systematic review and meta-analysis aggregated and examined the treatment effect of non-invasive brain stimulation (NIBS) (transcranial direct current stimulation and transcranial magnetic stimulation) on cognitive functions in people with traumatic brain injury (TBI). A systematic search was conducted using databases [...]

Authors:Farnoosh G, Akbaariqomix M, Badri T, Bagheri M, Izadi M. PMID: PMC8220995 DOI: 10.1016/j.arcmed.2021.06.006 Abstract Background: Melatonin has been known as an anti-inflammatory agent and immune modulator that may address progressive pathophysiology of coronavirus disease 2019 (COVID-19). Aim of the study: To evaluate the clinical efficacy of adjuvant, use of melatonin [...]

Authors: Colunga Biancatelli RM, Solopov P, Sharlow E, Lazo J, Marik PE, Catravas J PMID: 34156871 PMCID: PMC8384477 DOI: 10.1152/ajplung.00223.2021 Abstract Acute lung injury (ALI) leading to acute respiratory distress syndrome is the major cause of COVID-19 lethality. Cell entry of SARS-CoV-2 occurs via the interaction between its surface spike protein (SP) and angiotensin-converting enzyme-2 [...]

Authors: Cadegiani FA, McCoy J, Zimerman A, Mirza FN, Barros RN doi: https://doi.org/10.1101/2021.06.22.21259318 Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is mediated by the androgen-promoted protease, transmembrane protease, serine 2 (TMPRSS2). Previously, we have shown that treatment with proxalutamide, a non-steroidal androgen receptor antagonist, accelerates viral clearance and [...]

Authors: Bryant A, Lawrie TA, Dowswell T, Fordham E, Mitchell S, Hill SR et al. PMID: 34145166 PMCID: PMC8248252 DOI: 10.1097/MJT.0000000000001402 Abstract Background: Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. Areas of uncertainty: We assessed the [...]

Authors: Ahmadi R, Salari S, Reihani H, Eslami S. PMID: PMC8358331 DOI: 10.1002/fsn3.2226 Abstract Background: Curcumin, a natural polyphenolic compound, is proposed as a potential treatment option for patients with coronavirus disease by inhibiting the entry of virus to the cell, encapsulation of the virus and viral protease, as well as modulating various cellular signaling [...]

Authors: Duarte M, Pelorosso F, Nicolosi L, Salgado V, Vetulli H PMID: 34189447 PMCID: PMC8225700 DOI: 10.1016/j.eclinm.2021.100962 Abstract Background: Angiotensin receptor blockers (ARBs), such as telmisartan, have been postulated to treat Covid-19-induced lung inflammation. Methods: This is a parallel-group, randomized, two-arm, open-label, adaptive, multicenter superiority trial with 1:1 allocation ratio. Participants included patients from 18 [...]

Authors: Gold JE, Okyay R, Licht WE, Hurley DJ PMID: 34204243 PMCID: PMC8233978 DOI: 10.3390/pathogens10060763 Abstract Coronavirus disease 2019 (COVID-19) patients sometimes experience long-term symptoms following resolution of acute disease, including fatigue, brain fog, and rashes. Collectively these have become known as long COVID. Our aim was to first determine long COVID prevalence in 185 [...]

Authors: Lopes RD, Furtado RH, Bronhara B, Damiani LP, Barbosa LM. DOI:https://doi.org/10.1016/S0140-6736(21)01203-4 Abstract Background COVID-19 is associated with a prothrombotic state leading to adverse clinical outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised with COVID-19 is unknown. We aimed to compare the efficacy and safety of therapeutic versus prophylactic anticoagulation in this population. Methods [...]